Interestingly, novel approaches aimed at blocking the PD1-PD-L1 complex by oral small molecules or by PD-L1 B-cell peptide cancer vaccines able to stimulate the immune response are in advanced preclinical studies, pointing to the pivotal role of the PD1–PD-L1 axis in anticancer immune response [17,18]. This evidence concerns the gene CD274 and cancer.